Compare EXFY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | SERA |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 107.3M |
| IPO Year | 2021 | 2021 |
| Metric | EXFY | SERA |
|---|---|---|
| Price | $0.94 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 557.3K | 23.6K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $77,000.00 |
| Revenue This Year | $4.44 | $25.84 |
| Revenue Next Year | $0.56 | $715.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $1.17 | $1.37 |
| 52 Week High | $3.87 | $4.35 |
| Indicator | EXFY | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 25.73 | 31.88 |
| Support Level | N/A | $2.26 |
| Resistance Level | $1.54 | $3.45 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.23 | 9.43 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.